Treatment of Gambling Disorder With Fast Acting Opiate Antagonist, Naloxone Nasal Spray

Pilot Study: Treatment of Gambling Disorder With Fast Acting Opiate Antagonist, Naloxone Nasal Spray

Non-controlled pilot study. Two groups: Group A: naloxone nasal spray max 8 mg/per day; Group B: naloxone max 16 mg/per day. Study duration 8 weeks. Brief intervention.

Non-controlled pilot study. Two groups: Group A: naloxone nasal spray max 8 mg/per day; Group B: naloxone max 16 mg/per day. Study duration 8 weeks. No supportive therapy, but brief self-help booklet. Primary outcomes: adverse events, adherence and drop out analysis. Secondary outcome: gambling expenditure.

Inclusion Criteria:

• age over 18 years old
• South Oaks Gambling Scale (SOGS) 5 or over points
• possibility to keep a record with phone and send text messages
• fluent in Finnish Language

Exclusion Criteria:

• active drug use (specially opioids) current use - drugs screen
• nasal abnormality or mucosal irritability
• hepatitis c virus, kidney insufficiency
• psychosis, unstable mental health, risk suicide (Beck Depression Inventory)
• pregnancy and/or breast feeding
• persons according to Finnish Medical Law 188/1999 §7-10